Please use this identifier to cite or link to this item:
Title: Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma
Authors: Wudhikarn K.
Bunworasate U.
Julamanee J.
Lekhakula A.
Ekwattanakit S.
Khuhapinant A.
Niparuck P.
Chuncharunee S.
Numbenjapon T.
Prayongratana K.
Kanitsap N.
Wongkhantee S.
Makruasri N.
Wong P.
Norasetthada L.
Nawarawong W.
Sirijerachai C.
Chansung K.
Suwanban T.
Praditsuktavorn P.
Intragumtornchai T.
on behalf of Thai Lymphoma Study Group
Keywords: cyclophosphamide
cyclophosphamide plus doxorubicin plus etoposide plus prednisolone plus vincristine
lactate dehydrogenase
tumor marker
antineoplastic agent
advanced cancer
blood toxicity
cancer combination chemotherapy
cancer mortality
cancer prognosis
cancer regression
cancer survival
controlled study
disease severity
drug dose reduction
event free survival
febrile neutropenia
major clinical study
overall survival
peripheral T cell lymphoma
priority journal
standardized mortality ratio
systemic disease
therapy delay
disease free survival
health survey
Kaplan Meier method
middle aged
peripheral T cell lymphoma
treatment outcome
Antineoplastic Combined Chemotherapy Protocols
Disease-Free Survival
Kaplan-Meier Estimate
Lymphoma, T-Cell, Peripheral
Middle Aged
Progression-Free Survival
Public Health Surveillance
Treatment Outcome
Issue Date: 2019
Abstract: Event free survival at 24 months (EFS24) has been described as a powerful predictor for outcome in several subtypes of B cell lymphoma. However, it was limitedly described in T cell lymphoma. We explored the implication of EFS24 as a predictor marker for peripheral T cell lymphoma (PTCL). We reviewed 293 systemic PTCL patients at 13 nationwide major university hospitals in Thailand from 2007 to 2014. The median event free survival (EFS) and overall survival (OS) of PTCL patients in our cohort was 16.3 and 27.7 months with corresponding 2-year EFS and 2-year OS of 45.8% and 51.9%, respectively. A total of 118 patients achieved EFS24 (no events during the first 24 mo). Patients who achieved EFS24 had better OS than patients who did not (2-y OS 92% vs 18.8%; HR, 0.1; P <.001). The standardized mortality ratio of patients achieving EFS24 was 18.7 (95% CI, 14.6-22.8). Multivariable analysis demonstrated performance status, histologic subtype, remission status, and EFS24 achievement as independent predictors for OS. Our study affirmed the value of EFS24 as a powerful prognostic factor for PTCL. Further validation in prospective study setting is warranted. ©2019 John Wiley & Sons, Ltd.
ISSN: 2780232
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.

Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.